SEQUOIA III期研究:PEG化IL-10联合FOLFOX二线治疗转移性胰腺癌
SEQUOIA是一项随机全球III期研究,比较PEG化重组人IL-10(pegilodecakin)联合FOLFOX与FOLFOX二线治疗吉西他滨难治性转移性胰腺导管腺癌的疗效与安全性。共567例患者随机1:1分组,主要终点总生存期(OS)在两组间相似(中位5.8 vs 6.3个月;HR=1.045;95%CI 0.863-1.265),无进展生存期(PFS)和客观缓解率(ORR)亦无显著差异。联合组血液学毒性(血小板减少55% vs 20%、贫血40% vs 16%)和疲劳(61% vs 45%)发生率更高,但总体可管理。
要点
- PEG联合FOLFOX未改善吉西他滨难治性转移性胰腺癌的OS、PFS或ORR。
- 联合组血小板减少(55% vs 20%)和贫血(40% vs 16%)发生率显著升高,但毒性可管理。
- 探索性分析显示PEG增加IL-18、IFN-γ和颗粒酶B,降低TGF-β,符合IL-10R通路免疫刺激信号。
核心结论
- 在吉西他滨难治性转移性胰腺导管腺癌患者中,PEG联合FOLFOX对比FOLFOX未改善疗效。
- 联合治疗的安全性特征与既往PEG联合化疗观察一致,毒性可管理且可耐受。
研究设计与样本
- SEQUOIA是一项随机、全球、III期研究,比较PEG+FOLFOX与FOLFOX二线治疗吉西他滨难治性转移性胰腺导管腺癌。
- 2017年3月1日至2019年9月9日期间,567例患者按1:1随机分配至PEG+FOLFOX组(n=283)或FOLFOX组(n=284),按既往吉西他滨治疗和地区分层。
- 入组患者仅接受过一种含吉西他滨的治疗,主要终点为总生存期(OS)。
主要发现
- PEG+FOLFOX组与FOLFOX组的中位OS分别为5.8个月和6.3个月(HR=1.045;95%CI 0.863-1.265)。
- 两组中位PFS均为2.1个月(HR=0.981;95%CI 0.808-1.190),客观缓解率分别为4.6%和5.6%。
- PEG+FOLFOX组最常见的≥35%治疗中出现的不良事件包括血小板减少(55% vs 20%)、贫血(40% vs 16%)、疲劳(61% vs 45%)等。
- 探索性分析显示,加用PEG后总IL-18、干扰素-γ和颗粒酶B增加,转化生长因子-β降低。
临床怎么用
- 对于吉西他滨难治性转移性胰腺癌,不推荐在FOLFOX基础上常规联合PEG化IL-10。
- 联合治疗时需密切监测血小板减少和贫血等血液学毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: SEQUOIA compared efficacy and safety of adding pegilodecakin (PEG), a pegylated recombinant human interleukin (IL)-10, with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) in patients following progression on first-line gemcitabine-containing therapy with metastatic pancreatic ductal adenocarcinoma (PDAC). PATIENTS AND METHODS: SEQUOIA, a randomized, global phase III study, compared FOLFOX with PEG + FOLFOX as second line in gemcitabine-refractory PDAC. Patients were randomly assigned 1:1 (PEG + FOLFOX:FOLFOX) and stratified by prior gemcitabine and region. Eligible patients had only one prior gemcitabine-containing treatment. Primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), response evaluation per Response Evaluation Criteria in Solid Tumor (RECIST) 1.1, and safety. Exploratory analyses included biomarkers related to immune activation. RESULTS: Between March 1, 2017, and September 9, 2019, 567 patients were randomly assigned PEG + FOLFOX (n = 283) or FOLFOX (n = 284). Most (94.7%) patients received prior gemcitabine plus nab paclitaxel. OS was similar comparing PEG + FOLFOX versus FOLFOX (median: 5.8 v 6.3 months; hazard ratio = 1.045; 95% CI, 0.863 to 1.265). Also, PFS (median 2.1 v 2.1 months; hazard ratio = 0.981; 95% CI, 0.808 to 1.190) and objective response rate (4.6% v 5.6%) were similar between the treatment arms. Most common (≥ 35%) treatment-emergent adverse events in PEG + FOLFOX versus FOLFOX were thrombocytopenia (55% v 20%), anemia (40% v 16%), fatigue (61% v 45%), neutropenia (39% v 28%), abdominal pain (37% v 29%), nausea (45% v 41%), neuropathy (37% v 38%), and decreased appetite (35% v 31%). Exploratory analyses revealed increases in total IL-18, interferon (IFN)-γ, and granzyme B and decreases in transforming growth factor (TGF)-β with the addition of PEG. CONCLUSION: PEG added to FOLFOX did not improve efficacy in advanced gemcitabine-refractory PDAC. Safety findings were consistent as previously observed from PEG with chemotherapy; toxicity was manageable and tolerable. Exploratory pharmacodynamic results were consistent with immunostimulatory signals of the IL-10R pathway.
引用
- Hecht JR, Lonardi S, Bendell J, et al. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). J Clin Oncol. 2021. PMID: 33555926. doi:10.1200/JCO.20.02232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。